CASI Pharmaceuticals Receives China NMPA Approval for Phase 1/2 Clinical Trial of CID-103 in Renal Allograft AMR
I'm PortAI, I can summarize articles.
CASI Pharmaceuticals Inc. has received approval from the China National Medical Products Administration (NMPA) for a Phase 1/2 clinical trial of CID-103, aimed at treating renal allograft antibody-mediated rejection (AMR). The U.S. FDA has also approved an Investigational New Drug application for a Phase 1 study of CID-103 in adults with chronic active renal allograft AMR. These approvals enable CASI to conduct clinical studies in both China and the U.S.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments